Is it COVID-19?
Is it Flu?
Lab-comparable results in minutes
Verify potential infection quickly with a rapid microfluidic assay that provides actionable and lab-comparable results in 12 mins for patients suspected of Flu and/or COVID-19, to help decision making and guide treatment
Test benefits
- Microfluidic immunofluorescence assay
- Optimize patient and clinical flow - 1 sample, 3 results, 12 mins
- Sample type: nasal swab
- Prepared sample can also be used with LumiraDx SARS-CoV-2 & RSV Test*
- Easy to implement at point of care
- Time to result in as quick as 12 minutes
- No refrigeration storage required:
room temperature storage (2°C to 30 °C) - Portable Instrument for near-patient testing
- Minimal handling steps
*Swab used must be validated for use with both tests - refer to swab technical bulletins
Test workflow
The Instrument and Test Strips are integrated with several quality control checks to ensure the Instrument and Test are functioning correctly for every test run.
The workflow process is comprised of a simple sample prep along with step-by-step guidance of the Instrument to report a patient result in under 12 minutes from sample application.
Test performance
In clinical studies, the LumiraDx SARS-COV-2 & Flu A/B test demonstrated up to 95.5%, 83.3% and 80.0% positive agreement versus RT-PCR for detection of SARS-COV-2, Flu A and Flu B respectively.
Clinical agreement compared to RT-PCR
| SARS-CoV-2 | Flu A | Flu B | |
|---|---|---|---|
| PPA | up to 95.5%* | 83.3% | 80.0% |
| NPA | up to 99.0%* | 97.6% | 94.9% |
*Based on 0-12 days since symptom onset data set - See LumiraDx SARS-CoV & Flu A/B Product Insert for more details
Not all products are available in all countries and regions.
BetterHealthExperiencesOutcomes
Supporting healthier lives, for individuals, communities and wider society
Enabling responsive, personal relationships between patients and care teams.
Controlling and reducing costs to help ease pressure on healthcare budgets.